3.19
1.85%
-0.06
Neuraxis Inc stock is traded at $3.19, with a volume of 19,867.
It is down -1.85% in the last 24 hours and up +5.63% over the past month.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
See More
Previous Close:
$3.25
Open:
$3.17
24h Volume:
19,867
Relative Volume:
1.61
Market Cap:
$22.96M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-3.9549
EPS:
-0.8066
Net Cash Flow:
-
1W Performance:
+0.95%
1M Performance:
+5.63%
6M Performance:
+7.41%
1Y Performance:
+36.32%
Neuraxis Inc Stock (NRXS) Company Profile
Name
Neuraxis Inc
Sector
Industry
Phone
(812) 689-0791
Address
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
NRXS | 3.19 | 22.96M | 0 | 0 | 0 | -0.8066 |
VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Neuraxis Inc Stock (NRXS) Latest News
Critical Review: BioSig Technologies (NASDAQ:BSGM) vs. NeurAxis (NASDAQ:NRXS) - Defense World
NeurAxis, Inc. (NASDAQ:NRXS) Q3 2024 Earnings Call Transcript - MSN
Neuraxis secures $5 million in preferred stock sale By Investing.com - Investing.com Canada
Neuronetics Grants Inducement Awards to New Employees - MSN
NeurAxis Stock Surges After Strong Q3 Earnings And Expanded Coverage - Barchart
NeurAxis Stock Surges After Strong Q3 Earnings and Expanded Coverage - Yahoo Finance
NeurAxis reports 40% increase in revenues in Q3 2024 - Medical Buyer
NeurAxis Reports Strong Revenue Growth in Q3 2024 - TipRanks
Neuraxis Inc. (NRXS) Quarterly 10-Q Report - Quartzy
NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues - GlobeNewswire
NeurAxis Q3 Revenue Surges 40%, Expands Coverage to 35M Lives Amid FDA Milestone | NRXS Stock News - StockTitan
NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market - Building Indiana
NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024 - GlobeNewswire
NeurAxis (NRXS) Sets Q3 2024 Earnings Call for November 12 | Neuromodulation Leader | NRXS Stock News - StockTitan
IRIDEX (NASDAQ:IRIX) versus NeurAxis (NASDAQ:NRXS) Financial Survey - Defense World
NeurAxis Announces Capital Blue Cross Medical Policy Coverage for PENFS, effective October 1st 2024 - The Manila Times
NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation - GlobeNewswire
Neuraxis adjusts equity agreement, secures additional funding - Investing.com India
Creatd (NASDAQ:VOCL) Stock Price Down 4.4% – Should You Sell? - Defense World
Technip Energies (OTCMKTS:THNPY) Trading Up 0.7% – Here’s What Happened - Defense World
Vestas Wind Systems A/S (OTCMKTS:VWSYF) Shares Up 1.2% – Here’s What Happened - Defense World
Zacks Initiates Coverage of NeurAxis With Neutral Recommendation - Yahoo Finance
The Zacks Analyst Blog Highlights Costco Wholesale, Alibaba, GE Aerospace, Applied Energetics and NeurAxis - Yahoo Finance
Top Analyst Reports for Costco Wholesale, Alibaba & GE Aerospace - Yahoo Finance
NeurAxis (NASDAQ:NRXS) Trading Up 6% - Defense World
NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 - GlobeNewswire
Neuraxis issues shares in equity financing By Investing.com - Investing.com Australia
Neuraxis issues shares in equity financing - Investing.com
Fishers startup prepares to go public - Greenfield Daily Reporter
NeurAxis (NASDAQ:NRXS) Stock Price Down 2.2% - Defense World
NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024 - GlobeNewswire
Vagus Nerve Stimulators Market Projected to Witness Huge Growth - openPR
Neuraxis shareholders approve key proposals at annual meeting - Investing.com
NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024 - GlobeNewswire
NeurAxis revenue down 5.3% to USD 611.5K in Q2 2024 - Medical Buyer
NeurAxis, Inc. (NRXS) Q2 2024 Earnings Call Transcript - Seeking Alpha
Contrasting Sonova (OTCMKTS:SONVY) & NeurAxis (NASDAQ:NRXS) - Defense World
NRXS Stock Earnings: Neuraxis Reported Results for Q2 2024 - MSN
NeurAxis Reports Second Quarter 2024 Financial Results - GlobeNewswire
NeurAxis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Vagus Nerve Stimulators Market Is Booming Worldwide 2024-2031 | - openPR
NeurAxis to Host Second Quarter 2024 Results and Business Update Call on Friday, August 9, 2024 - GlobeNewswire
Neuraxis Inc Stock (NRXS) Financials Data
There is no financial data for Neuraxis Inc (NRXS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Cap:
|
Volume (24h):